| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 06/02/2005 | CA2546674A1 Plants having modified growth characteristics and a method for making the same |
| 06/02/2005 | CA2546406A1 Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer |
| 06/02/2005 | CA2546355A1 Novel atypical pneumonia-causing virus |
| 06/02/2005 | CA2546285A1 Compositions and methods for the treatment of tumor of hematopoietic origin |
| 06/02/2005 | CA2545944A1 Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure |
| 06/02/2005 | CA2545886A1 Methods of characterizing infectious bursal disease virus |
| 06/02/2005 | CA2545855A1 Alpha 1-antitrypsin compositions and treatment methods using such compositions |
| 06/02/2005 | CA2545693A1 Modification of protein glycosylation in methylotrophic yeast |
| 06/02/2005 | CA2545251A1 Hairless protein-interacting partner complexes and methods thereof for the beautification and/or improvement of mammalian skin |
| 06/02/2005 | CA2545049A1 Method for proliferating cardiomyocytes |
| 06/02/2005 | CA2545024A1 Fusion proteins and methods of cleavage of such proteins |
| 06/02/2005 | CA2544234A1 Fibres embedded in a glassy protein |
| 06/02/2005 | CA2543897A1 Compositions and methods for screening pro-apoptotic compounds |
| 06/02/2005 | CA2543072A1 Compositions comprising melittin-derived peptides and methods for the potentiation of immune responses against target antigens |
| 06/02/2005 | CA2532881A1 Anthrax vaccine |
| 06/02/2005 | CA2527680A1 Markers for responsiveness to an erbb receptor tyrosine kinase inhibitor |
| 06/02/2005 | CA2526860A1 Synthetic mammalian retrotransposon gene |
| 06/01/2005 | EP1536234A2 Soluble CTLA4 mutant molecules and uses thereof |
| 06/01/2005 | EP1536024A1 New Hepatitis C virus clade and phototype sequences thereof |
| 06/01/2005 | EP1536015A1 Promoters for expression in modified vaccinia virus ankara |
| 06/01/2005 | EP1536013A1 Dna sequence useful in diagnosing hepatitis and polypeptide encoded thereby |
| 06/01/2005 | EP1536010A1 Preventives/remedies for cancer |
| 06/01/2005 | EP1536009A1 Hla-a24-restricted cancer antigen peptide |
| 06/01/2005 | EP1536006A1 Cancer antigens and utilization thereof |
| 06/01/2005 | EP1536002A1 Yeast-origin promoter and vector and expression system using the same |
| 06/01/2005 | EP1535995A1 Polynucleotides encoding the antigenic HIV type C env polypeptide and uses thereof |
| 06/01/2005 | EP1535929A2 Megakaryocyte stimulating factors |
| 06/01/2005 | EP1535928A2 Omp85 proteins of Neisseria gonorrhoeae and Neisseria meningitidis, compositions containing same and methods of use thereof |
| 06/01/2005 | EP1535927A1 Hbv precore protein capable of forming particles |
| 06/01/2005 | EP1535628A2 HBV/HCV virus-like particle |
| 06/01/2005 | EP1535627A1 Recombinant bcg vaccine |
| 06/01/2005 | EP1535512A1 DISEASE MODEL ANIMAL CARRYING FOREIGN PPARa GENE TRANSFERRED THEREINTO AND USE THEREOF |
| 06/01/2005 | EP1535076A2 Polypeptide biomarkers for diagnosing alzheimer's disease |
| 06/01/2005 | EP1535074A1 Method for detection of bioactive peptides |
| 06/01/2005 | EP1535067A2 PAPSSs AS MODIFIERS OF THE AXIN PATHWAY AND METHODS OF USE |
| 06/01/2005 | EP1535065A2 Neuroprotective synergy of erythropoietin and insulin-like growth factor |
| 06/01/2005 | EP1534862A2 Modulators of rabggt and methods of use thereof |
| 06/01/2005 | EP1534860A2 Methods of screening for schizophrenia |
| 06/01/2005 | EP1534852A2 CSNK1GS AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE |
| 06/01/2005 | EP1534846A1 Replicons of pestiviruses that do not express c and or e1 protein and infectious viral particles containing same, that can be used in vaccines |
| 06/01/2005 | EP1534845A1 Generation of recombinant influenza virus using baculovirus delivery vector |
| 06/01/2005 | EP1534844A2 Method for improving corn starch extractability |
| 06/01/2005 | EP1534843A2 Sugar and lipid metabolism regulators in plants iv |
| 06/01/2005 | EP1534836A1 Mutant forms of meningococcal adp-ribosylating toxin |
| 06/01/2005 | EP1534834A2 Denaturant stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same, their uses and methods of increasing a specific activity thereof |
| 06/01/2005 | EP1534833A1 Mammalian grainyhead transcription factors |
| 06/01/2005 | EP1534831A2 Composition, method and use of bi-functional biomaterials |
| 06/01/2005 | EP1534830A1 In vitro peptide expression libraray |
| 06/01/2005 | EP1534829A2 Plant defensins |
| 06/01/2005 | EP1534826A2 Transgenic rat and the use thereof in the animal model for human huntingdon's disease and nuclear constructs, vectors and cells for the production thereof |
| 06/01/2005 | EP1534750A2 Therapeutic uses of monoclonal antibodies to the angiotensin-ii type-1 receptor |
| 06/01/2005 | EP1534749A2 Variant integrin polypeptides and uses thereof |
| 06/01/2005 | EP1534748A2 Fusion proteins and methods of producing same |
| 06/01/2005 | EP1534747A2 Polymorphisms in the human genes for oct1 and their use in diagnostic and therapeutic applications |
| 06/01/2005 | EP1534746A2 Composite peptide compounds for diagnosis and treatment of diseases caused by prion proteins |
| 06/01/2005 | EP1534745A2 A genomic approach to identification of novel broad-spectrum antimicrobial peptides from bony fish |
| 06/01/2005 | EP1534744A1 Altered insulin-like growth factor binding proteins |
| 06/01/2005 | EP1534743A1 Scorpion peptide as hypotensive agent |
| 06/01/2005 | EP1534742A1 Compositions and methods for treatment and prophylaxis of infections caused by gram positive bacteria |
| 06/01/2005 | EP1534741A1 Fiber-shaping peptides capable of interacting with self-assembling peptides |
| 06/01/2005 | EP1534740A2 Composition and method for stabilising biomolecules |
| 06/01/2005 | EP1534739A2 Identification of polynucleotides and polypeptide for predicting activity of compounds that interact with protein tyrosine kinases and/or protein tyrosine kinase pathways |
| 06/01/2005 | EP1534738A2 Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| 06/01/2005 | EP1534737A2 Peptide antagonists of tgf-beta family members and therapeutic uses thereof |
| 06/01/2005 | EP1534736A2 Nogo receptor antagonists |
| 06/01/2005 | EP1534731A1 Bmp-2 estrogen responsive element and methods of using the same |
| 06/01/2005 | EP1534730A2 Modified transferin-antibody fusion proteins |
| 06/01/2005 | EP1534729A2 Variants of nedd4l associated with hypertension and viral budding |
| 06/01/2005 | EP1534718A1 Chemical synthesis of reagents for peptide coupling |
| 06/01/2005 | EP1534658A2 Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| 06/01/2005 | EP1534344A2 Viruses and virus-like particles for multiple antigen and target display |
| 06/01/2005 | EP1534334A1 Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| 06/01/2005 | EP1534331A2 Membrane associated tumor endothelium markers |
| 06/01/2005 | EP1534328A2 Protective antigens for the control of ixodes species infestations |
| 06/01/2005 | EP1534325A2 Random transposon insertion in staphylococcus aureus and use thereof to identify essential genes |
| 06/01/2005 | EP1534322A1 Minibrain homologous proteins involved in the regulation of energy homeostasis |
| 06/01/2005 | EP1534319A2 Use of compounds capable of inhibiting the proteolytic processing of semaphorins for prevention, treatment, diagnosis and prognosis of an invasive disease |
| 06/01/2005 | EP1534318A2 Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis |
| 06/01/2005 | EP1534317A2 N-terminally truncated galectin-3 and antibodies for treating cancer |
| 06/01/2005 | EP1534315A2 Increasing of the resorption of substances via skin and mucous membranes |
| 06/01/2005 | EP1534311A2 Method for identifying modulators of ion channels |
| 06/01/2005 | EP1534310A2 Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases |
| 06/01/2005 | EP1534308A2 Peptides with growth inhibitory action |
| 06/01/2005 | EP1534306A2 Defensins: use as antiviral agents |
| 06/01/2005 | EP1534256A2 Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier |
| 06/01/2005 | EP1534073A2 Methods for identifying modulators of mda-7 mediated apoptosis |
| 06/01/2005 | EP1534064A2 Transgenic non-human mammals expressing a reporter nucleic acid under the regulation of androgen response elements |
| 06/01/2005 | EP1490509A4 Modulating insulin receptor signaling |
| 06/01/2005 | EP1483397A4 Oligomeric molecules and uses thereof |
| 06/01/2005 | EP1451291A4 Methods for identifying, isolating, and controlling the growth of estrogen-responsive cells |
| 06/01/2005 | EP1423002A4 Use of cross-linked, covalently bound urokinase plasminogen activator (scupa)-urokinase plasminogen activator receptor (supar) complex as a fibrinolytic agent |
| 06/01/2005 | EP1404362A4 Signal-1/signal-2 bifunctional peptide inhibitors |
| 06/01/2005 | EP1339747B1 Membrane fusion proteins derived from reovirus |
| 06/01/2005 | EP1311162B1 Bacillus thurigiensis crystal protein hybrids |
| 06/01/2005 | EP1283846A4 Methods of detecting interactions between proteins, peptides or libraries thereof using fusion proteins |
| 06/01/2005 | EP1263884B1 Process for the preparation of micronised collagen, and its therapeutic applications |
| 06/01/2005 | EP1255775B1 Process for the preparation of a mucosal form of the eosinophil cationic protein (ecp) |
| 06/01/2005 | EP1169282B1 Site-specific isotopically-labeled proteins, amino acids, and biochemical precursors therefor |
| 06/01/2005 | EP1042460B1 Brain or heart cyclic nucleotide gated ion channel compounds and uses thereof |
| 06/01/2005 | EP0794963B1 Xanthine derivatives compounds useful for activating chloride conductance in animal cells |